MetaCap

Bio-Rad Laboratories Inc. Class A (BIO)

NYSE: BIOIndustrialsBiotechnology: Laboratory Analytical InstrumentsUSD

358.90-8.60 (-2.34%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BIO stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
$37.64
52-week range
236.73 – 396.23
Day range
353.31 – 369.44
Volume / Avg
182.30K / 257.70K
Beta
—

52-week range

$236.73$396.23

BIO stock today

Shares of Bio-Rad Laboratories (BIO) finished lower on Nov 20 at $358.90, a drop of 2.34% or $8.60 per share, versus the S&P 500's 3.70% decline. At this level, BIO sits in the middle of its 52-week range of $236.73 to $396.23: 9.4% below the high, set on Aug 27, 2026 and 51.6% above the low. BIO is up 18.5% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 13.3%.

Bio-Rad Laboratories trades at 9.5x its trailing twelve-month earnings per share of $37.64. Its forward P/E of 36.2x is higher than the trailing multiple, which means analysts expect earnings to decline over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Bio-Rad Laboratories

Company profile

Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics.

Industry
Biotechnology: Laboratory Analytical Instruments
CEO
Mr. Norman D. Schwartz
Headquarters
Hercules, CA
Employees
7,450
IPO year
1980

Financial highlights

Full financials

In fiscal 2025, Bio-Rad Laboratories generated $2.58 billion in revenue, up 0.7% from fiscal 2024. Net income was $759.9 million, for a net margin of 29.4% versus a median of -23.9% in the prior 5 years. Gross margin was 51.9% (down from 53.7%) and operating margin 1.8%.

Bio-Rad Laboratories annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$2.58B$2.57B$2.67B$2.80B$2.92B
Growth+0.65%-3.92%-4.67%-4.12%+14.81%
Net income$759.90M$-1.84B$-637.30M$-3.63B$4.25B
EPS (diluted)$27.85$-65.36$-21.82$-121.79$140.83

Analyst forecast

Forecast

Consensus (3 analysts)

hold

Avg. price target

$356.67-0.62%

  • Strong buy 1
  • Buy 0
  • Hold 1
  • Sell 0
  • Strong sell 1

Target range

Low $280.00High $440.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$17.02 vs $2.61
Surprise
+552.11%

BIO news

All BIO news

Bio-Rad Laboratories peers

Industrials sector
BIO peer companies
CompanyPrice% ChgMarket capCompare
AVTRAvantor Inc.14.84-1.85%$10.06Bvs BIO
BRKRBruker Corporation56.46-9.08%$8.62Bvs BIO
TXG10x Genomics Inc. Class A51.80-9.72%$6.81Bvs BIO
RVTYRevvity Inc.145.22-4.20%$16.21Bvs BIO
ALMRAlamar Biosciences Inc.26.48-7.67%$1.84Bvs BIO
CTKBCytek Biosciences Inc.6.12-3.16%$800.40Mvs BIO
PACBPacific Biosciences of California Inc.1.63-7.39%$508.95Mvs BIO
NAUTNautilus Biotechnology Inc.2.12-2.30%$270.03Mvs BIO

Indexes, lists and sector

Bio-Rad Laboratories stock FAQ

What is Bio-Rad Laboratories's stock price today?

BIO last traded at $358.90 as of Nov 20, 4:00 PM EST, down 2.34% on the day. Prices are delayed at least 15 minutes.

Does Bio-Rad Laboratories pay a dividend?

No. Bio-Rad Laboratories does not currently pay a regular cash dividend.

What is BIO's P/E ratio?

BIO trades at a trailing P/E ratio of 9.54 and a forward P/E of 36.23.

Who is Bio-Rad Laboratories's CEO?

Mr. Norman D. Schwartz is the chief executive officer of Bio-Rad Laboratories Inc. Class A, which has about 7,450 employees.

Has BIO ever split its stock?

Yes. The most recent BIO stock split was a 2-for-1 split on Mar 8, 2002, one of 5 splits on record.

What is the BIO 52-week high?

The 52-week high for BIO is $396.23 and the 52-week low is $236.73. The stock is currently 9.4% below its high.

Compare BIO